Clinical Trial Update: Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye [Phase 3]

View source ↗

Summary

Phase 3 trial update for topical ophthalmic AGN-195263 in evaporative dry eye has been terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dry Eye Syndromes

Drugs mentioned

• AGN-195263

Snippet

Sponsor: Allergan | Conditions: Dry Eye Syndromes | Phase 3 | Status: TERMINATED | Results posted: 2018-11-30